TABLE 1.
Characteristics of patients in each reported ase
| PATIENT CHARACTERISTICS | CASE 1 | CASE 2 |
|---|---|---|
| Sex | Female | Female |
| Age | 45 | 37 |
| Ethnicity | Caucasian | African American |
| BMI (most recent) | 30.37kg/m3 | 42.93kg/m3 |
| Comorbidities | Ulcerative colitis status post colectomy, type II diabetes mellitus, hypertension, tobacco use, depression | Stage IV chronic kidney disease, Type II diabetes mellitus, hypertension, obesity, depression |
| Duration of diagnosis prior to canakinumab | 15 months since diagnosis of concomitant PG and HS | 149 months since diagnosis of PASH syndrome |
| Prior treatments | Dapsone, infliximab, adalimumab, cyclosporine, colchicine, mycophenolate, ustekinumab, methotrexate | Dapsone, minocycline, adalimumab, methotrexate, infliximab |
| Canakinumab dose | Canakinumab 150mg SQ q 2 months × 2 doses | Canakinumab 150mg SQ q week × 4 weeks |
| Anakinra dose | Anakinra 100mg SQ daily ×3 weeks | N/A |
BMI: body mass index; PG: pyoderma gangrenosum; HS: hydradenitis suppurativa; PASH: pyoderma gangrenosum-acne-hidradenitis syndrome; SQ: subcutaneous; q: every; N/A: not applicable